BellBrook Labs Introduces the Transcreener™ KINASE TR-FRET Assay
News Dec 11, 2006
BellBrook has introduced the Transcreener™ Assays which rely on homogenous immunodetection of nucleotides, which means robust, generic detection of entire families of drug targets.
With the introduction of the Transcreener™ KINASE TR-FRET Assay, BellBrook is extending ADP detection beyond its original far-red FP format.
The Transcreener™ KINASE TR-FRET Assay is a fluorescence resonance energy transfer (TR-FRET) immunoassay for the detection of ADP. It relies on a proprietary monoclonal antibody that differentiates ADP from ATP with high selectivity.
The Transcreener™ KINASE TR-FRET Assay can be used for enzyme class that produces ADP, including protein, lipid or carbohydrate kinases, ATPases, DNA helicases, and carboxyltransferases.
Designed as a simple “mix and read” assay, it can provide a signal at low ATP conversion resulting in overall Z’> 0.6. The assay can accommodate from 1 µM to 100 µM ATP.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019